💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

Sequoia Fund sold 1.5 mln Valeant shares - WSJ

Published 2016-03-21, 08:10 p/m
© Reuters.  Sequoia Fund sold 1.5 mln Valeant shares - WSJ
BHC
-

March 21 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) International
Inc's VRX.N largest stakeholder, Sequoia Fund, said it sold
about 1.5 million shares of the company's stock last week, the
Wall Street Journal reported on Monday.
Ruane, Cunniff & Goldfarb Inc, which runs Sequoia, told the
Journal that the Valeant shares were sold to reduce investor
taxes by booking capital losses. (http://on.wsj.com/1UzKtVx)
The shares were bought in October, Ruane, Cunniff &
Goldfarb's executive vice president, David Poppe, told the
Journal.
In January, Ruane, Cunniff & Goldfarb, long known for its
ties to Warren Buffett, was sued by shareholders who claimed it
recklessly took a huge stake in the embattled drug company
Valeant, causing more than $2 billion in losses.
Valeant, a target of a securities investigation and under
scrutiny for its pricing and accounting practices, said on
Monday that its longtime chief executive officer was leaving
just three weeks after returning from a medical leave.

Ruane, Cunniff could not immediately be reached outside of
regular business hours.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.